In the biopharmaceutical industry, laboratory capabilities serve as a core benchmark for measuring a company’s technical strength. Driven by an unwavering commitment to technical compliance and innovative excellence,Changsha Morning Shine Co., Ltd. first obtained laboratory accreditation from the China National Accreditation Service for Conformity Assessment (CNAS) in May 2022. In July 2023, the company successfully completed site change and scope expansion reviews, adding critical testing capabilities such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. This accreditation not only signifies that its laboratory management system meets international standards but also represents a major milestone in addressing cutting-edge technical challenges in the industry, injecting strong momentum into the company’s growth.